This Article Full Text Full Text (PDF) eLetters: Submit a response to this article Purchase Article View Shopping Cart Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hejna, M. Articles by Raderer, M. Search for Related Content PubMed PubMed Citation Articles by Hejna, M. Articles by Raderer, M.

Postoperative Chemotherapy for Gastric Cancer

^a Department of Internal Medicine I, Division of Oncology, ^b Center of Excellence in Clinical and Experimental Oncology, University of Vienna, Vienna, Austria

Key Words. Gastric cancer • Adjuvant treatment • Chemotherapy • Review

Correspondence: Michael Hejna, M.D., Department of Internal Medicine I, Division of Oncology, University of Vienna, Waehringer Guertel 18–20, A-1090 Vienna, Austria. Telephone: +431 40400 2296; Fax: +431 40400 2296; e-mail: michael.hejna{at}meduniwien.ac.at

Introduction. Adjuvant chemotherapy for gastric cancer after potentially curative surgery has been under clinical investigation for more than four decades. However, potentially curative resection can be performed in only 30%–50% of patients. The objective of this article is to review briefly the clinical trials available in the current literature using adjuvant cytotoxic chemotherapy in patients with gastric cancer after potentially curative surgical resection.

Methods. Computerized (MEDLINE) and manual searches were performed to identify papers published on this topic between 1965 and 2005. Only articles with an English abstract were reviewed for inclusion; information abstracted included histologic proof of diagnosis, number of patients, dose and modality of treatment, survival duration, and side effects.

Results. Forty-three reports were identified. Single-agent chemotherapy was evaluated in four clinical trials, and postoperative combination chemotherapy was evaluated in 33 trials. Furthermore, we identified five meta-analyses. Five-year survival rates ranged from 12%–91.2%, and the median survival durations were 13–60+ months. Adjuvant chemotherapy, when compared with surgery alone, seems to result in longer survival.

Conclusion. The high rate of recurrence, even in patients undergoing state-of-the art curative resection, suggests that effective adjuvant chemotherapy might indeed be an attractive concept to improve the overall outcome of patients with gastric cancer. However, because there is no standard regimen for postoperative treatment at the moment, patients with R0-resected (no residual tumors) gastric cancer should be offered the opportunity to participate in prospective clinical trials.

This article has been cited by other articles:

				G Muhlmann, G Spizzo, J Gostner, M Zitt, H Maier, P Moser, G Gastl, M Zitt, H M Muller, R Margreiter, et al. TROP2 expression as prognostic marker for gastric carcinoma J. Clin. Pathol., February 1, 2009; 62(2): 152 - 158. [Abstract] [Full Text] [PDF]

				H.-C. Jeung, Y. W. Moon, S. Y. Rha, N. C. Yoo, J. K. Roh, S. H. Noh, J. S. Min, B. S. Kim, and H. C. Chung Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up Ann. Onc., March 1, 2008; 19(3): 520 - 526. [Abstract] [Full Text] [PDF]